Modality
ADC
MOA
ALKi
Target
CDK2
Pathway
PD-1/PD-L1
BCCParkinson'sMeso
Development Pipeline
Preclinical
~Oct 2020
→ ~Jan 2022
Phase 1
Apr 2022
→ Oct 2028
Phase 1Current
NCT04398615
186 pts·Meso
2022-04→2028-10·Active
186 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-10-012.5y awayPh2 Data· Meso
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1/2
Active
Catalysts
Ph2 Data
2028-10-01 · 2.5y away
Meso
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04398615 | Phase 1/2 | Meso | Active | 186 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| AMG-415 | Amgen | Phase 1 | CDK2 |